Physician profile
Mirela Ungureanu
NPI 1225240377
$2,192.01
in general payments reported to CMS, 2019-2025
31 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $273 · 2020: $150 · 2021: $37.21 · 2022: $17.06 · 2023: $460 · 2024: $794 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,714.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.90 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $388.25 | 2019-2025 | |
| Lilly USA, LLC | $244.71 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $125.70 | 2020-2025 | Breztri, Farxiga |
| Ironshore Pharmaceuticals INC. | $98.87 | 2024 | |
| Amgen INC. | $88.27 | 2019-2025 | Otezla, Repatha |
| Pfizer INC. | $84.60 | 2019-2025 | |
| Exact Sciences Corporation | $82.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Glaxosmithkline, LLC. | $73.06 | 2019-2025 | Trelegy Ellipta |
| Dexcom, INC. | $51.46 | 2023-2024 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $44.94 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Sanofi Pasteur INC. | $42.89 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.97 | 2020-2023 | Tradjenta |
| Abbvie INC. | $37.21 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.13 | 2023-2024 | Trintellix |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $30.51 | 2025 | Ohtuvayre |
| Corium, LLC | $30.05 | 2023-2025 | Azstarys |
| Sanofi-Aventis U.S. LLC | $26.66 | 2019-2020 | |
| Cranial Technologies, INC | $26.42 | 2023 | Doc Band |
| Collegium Pharmaceutical, INC. | $24.35 | 2025 | Jornay Pm |
| Alkermes, INC. | $22.60 | 2024 | Vivitrol |
| Ibsa Pharma INC. | $20.21 | 2024 | Licart, Tirosint |
| Phathom Pharmaceuticals, INC. | $20.14 | 2024 | Voquezna |
| Teva Pharmaceuticals USA, INC. | $19.77 | 2019 | |
| Hologic Sales and Service, LLC | $19.58 | 2024 | Aptima |
| Bayer Healthcare Pharmaceuticals INC. | $19.08 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $17.80 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.24 | 2019 | |
| Inspire Medical Systems, INC. | $17.22 | 2025 | Inspire |
| Amarin Pharma, INC. | $12.44 | 2020 | |
| Sarepta Therapeutics, INC. | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mirela Ungureanu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.